Luke C. Pilling

This study identifies genetic variants causal for multiple long-term conditions, revealing shared biological pathways and potential drug targets while highlighting adverse effects of interventions.

The paper develops a proteomic signature (HPS) to predict healthspan, showing it predicts mortality and age-related diseases better than other biological age measures.

This study integrates primary care and genetic data to identify multimorbidity patterns and shared genetics across 72 chronic conditions, revealing both concordant and discordant relationships.

The paper develops a proteomic aging clock (PAC) that predicts all-cause mortality and disease outcomes in middle-aged and older adults using plasma protein data.

This paper combines pharmacogenetic variants and polygenic scores for patient characteristics to improve prediction of clinical outcomes in Calcium Channel Blocker treatment.

This study shows that polygenic risk scores for iron levels and related diseases increase the risk of clinical outcomes in HFE p.C282Y homozygotes, but not in females or compound heterozygotes.

This study finds that CYP2C19 loss-of-function variants are associated with increased risk of ischemic stroke and MI in patients on long-term clopidogrel therapy in primary care.

The paper introduces the TWIST framework for causal inference in pharmacogenetics, showing how to combine different estimation strategies to improve robustness and efficiency in estimating genetically moderated treatment effects.

This study performs a genome-wide association study of frailty index to identify genetic signals and pathways, finding synapse function enrichment and associations with educational attainment.

This study identifies genetic associations for two biological age measures, revealing distinct aging phenotypes linked to different pathways and APOE variants.

This study identifies 15 genetic loci associated with muscle weakness in older adults through a large meta-analysis, revealing new pathways linked to aging and health outcomes.

The paper re-evaluates the association between ApoE e4e4 genotype and COVID-19 test positivity and mortality in the UK Biobank cohort, finding increased risks for both outcomes compared to e3e3 genotype.

The paper assesses the effects of ApoE e2 variants on aging-related outcomes using UK Biobank data, finding protective effects for e2e3 but not e2e2.

The paper investigates the association between ApoE e4 genotype and severe COVID-19 in the UK Biobank community cohort, finding a link with increased risk of severe outcomes.

This study identifies genetic variants associated with red blood cell distribution width (RDW) in 166,666 UK Biobank volunteers, linking RDW to aging-related pathways and health outcomes.

The study tests a reported healthy ageing gene expression score in two cohorts and finds no association with age or related phenotypes.